Predictive Value of 1-Hour Glucose Elevations during Oral Glucose Tolerance Testing for Cystic Fibrosis-Related Diabetes

Table 2

Baseline characteristics of patients who did or did not develop CFRD during study period.

	CF without diabetes	CFRD progressors	value
	n = 149	n = 28
Male, n (%)	82 (55%)	12 (43%)	0.33
Race, n (%)			0.75
Caucasian	119 (80%)	23 (82%)
Other	30 (20%)	5 (18%)
Age (years)	12.53 ± 2.68	11.85 ± 1.91	0.20
Fasting OGTT (mg/dL)	90 ± 8	89 ± 9	0.49
1-hour glucose (mg/dL)	160 ± 44	173 ± 48	0.16
2-hour glucose (mg/dL)	114 ± 32	127 ± 39	0.07
BMI% ile	19.26 ± 3.19	17.59 ± 1.57	0.09
HbA1c (%)	5.5 ± 0.4	5.6 ± 0.3	0.19
Genotype, n (%)			0.15
Residual function mutations	14 (9%)	0 (0%)
2 minimal function mutations	131 (88%)	28 (100%)
Unknown	4 (3%)	0 (0%)
FEV1% predicted	92.29 ± 16.14	81.69 ± 9.31	0.08
FVC% predicted	99.38 ± 14.28	92.13 ± 7.43	0.17
FEV1/FVC	0.93 ± 0.08	0.89 ± 0.08	0.23
Time between 1^st and last visit (years)	3.24 ± 1.34	2.75 ± 1.73	0.09
Age at CFRD diagnosis (years)	—	15.20 ± 2.57